Skip to main content
SpringerLink
Log in

Myc — Proteinstabilität als Angriffsziel für zielgerichtete Therapien

  • Wissenschaft
  • Onkogene Transkriptionsfaktoren
  • Published:
BIOspektrum Aims and scope

Abstract

The Myc transcription factor family affects the expression of a large group of genes that play an important role during tumourigenesis. Therefore, deregulated expression of the MYC gene family is a hallmark of multiple human tumours. An indirect reduction of Myc-protein levels due to interference with protein-stabilizing mechanisms could be a promising therapeutic approach targeting Myc-dependent tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Sheiness D, Fanshier L, Bishop JM (1978) Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J Virol 28:600–610

    PubMed  CAS  Google Scholar 

  2. Dang CV (2012) MYC on the path to cancer. Cell 149:22–35

    Article  PubMed  CAS  Google Scholar 

  3. Soucek L, Whitfield JR, Sodir NM et al. (2013) Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 27:504–513

    Article  PubMed  CAS  Google Scholar 

  4. Popov N, Wanzel M, Madiredjo M et al. (2007) The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 9:765–774

    Article  PubMed  CAS  Google Scholar 

  5. Chauhan D, Tian Z, Nicholson B et al. (2012) A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22:345–358

    Article  PubMed  CAS  Google Scholar 

  6. Otto T, Horn S, Brockmann M et al. (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15:67–78

    Article  PubMed  CAS  Google Scholar 

  7. Brockmann M, Poon E, Berry T et al. (2013) Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24:75–89

    Article  PubMed  CAS  Google Scholar 

  8. Fraile JM, Quesada V, Rodríguez D et al. (2012) Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 31:2373–2378

    Article  PubMed  CAS  Google Scholar 

  9. Kaelin WG Jr. (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689–698

    Article  PubMed  CAS  Google Scholar 

  10. Mendes-Pereira AM, Martin SA, Brough R et al. (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1:315–322

    Article  PubMed  CAS  Google Scholar 

  11. Liu L, Ulbrich J, Müller J et al. (2012) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 483:608–612

    Article  PubMed  CAS  Google Scholar 

  12. Sloane DA, Trikic MZ, Chu ML et al. (2010) Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem Biol 5:563–576

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lehrstuhl für Biochemie und Molekularbiologie, Universität Würzburg, Würzburg, Germany

    Anne Carstensen & Martin Eilers

  2. The Netherlands Cancer Institute, Amsterdam, Niederlande

    Markus Brockmann

  3. Theodor-Boveri-Institut Lehrstuhl für Biochemie und Molekularbiologie, Universität Würzburg, Am Hubland, D-97074, Würzburg, Germany

    Martin Eilers

Authors
  1. Anne Carstensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Brockmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Eilers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Eilers.

Additional information

Anne Carstensen Jahrgang 1986. 2005–2010 Studium der Molekularen Biomedizin an der Universität Bonn. Seit 2010 Promotionsstudentin bei Prof. Dr. M. Eilers, Universität Würzburg.

Markus Brockmann 2001–2007 Biochemiestudium an der Universität Bielefeld und University of Notre Dame, South Bend, IN, USA. 2007–2013 Promotion an den Universitäten Marburg und Würzburg. Seit 2013 Postdoc am Netherlands Cancer Institute, Amsterdam, Niederlande.

Martin Eilers Jahrgang 1960. 1978–1984 Chemie- und Biochemiestudium an den Universitäten Münster, Tübingen, Edinburgh, UK. 1988 Promotion am Biozentrum der Universität Basel, Schweiz, bei Prof. Dr. G. Schatz. 1988–1990 Postdoc an der University of California, San Francisco, USA bei Dr. M. Bishop. 1991–1996 Forschungsgruppen — leiter am Zentrum für Molekulare Biologie der Universität Heidelberg. 1997–2008 Professor für Molekularbiologie (C4), Universität Marburg. Seit 2008 Professor für Biochemie und Molekularbiologie, Universität Würzburg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carstensen, A., Brockmann, M. & Eilers, M. Myc — Proteinstabilität als Angriffsziel für zielgerichtete Therapien. Biospektrum 19, 726–729 (2013). https://doi.org/10.1007/s12268-013-0382-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12268-013-0382-1

Search

Navigation